At least two groups have posted early data on T-cell tests for Covid-19; now Qiagen has licensed tech to make its own.
Vir’s tie-up with Glaxo leads recent deal activities aiming to treat the new coronavirus.
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.